HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mary CEO ‘Not Too Concerned’ About China’s CBD Cosmetics Ban

Executive Summary

Mary Agrotechnologies CEO Frank Qin says he is “not too concerned” about China's recent  CBD cosmetics ban, despite his company's plans to build a 150,000 square-foot cultivation and extraction plant in Yunnan, with the aim of supplying the domestic CBD market and exporting overseas.

You may also be interested in...



China’s CBD Cosmetics Shutdown Not Harshing Yooma’s Mellow

Yooma Wellness, a producer of cannabinoid ingredients and owner of brands including What the Hemp, says better-than-expected growth in other markets should offset the impact of China’s ban on CBD in cosmetics.

OTC Shortages Top Of Mind For North American, European and Asia Pacific Consumers

An overwhelming majority of consumers surveyed by IT consultancy Capgemini are concerned they will not be able to obtain the OTC health products they require or want. In the event of shortages – which are currently affecting consumers across Europe – many respondents said they would substitute with another brand, or in some cases not purchase at all.

OTC Codeine Cough Syrups Meet UK Conditions For Rx Reverse Switch, Says Expert Body

Could codiene linctus cough syrups be reverse-switched from OTC to Rx status in the UK? A panel of independent medicines experts suggests they should be, based on UK drugs law and their use in illegal cocktail Purple Drank.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel